High urgency

DEA Diversion Control Division | Home

Detected July 6, 2026 · in Telehealth Cross-State Licensing

DEA temporarily places mitragynine pseudoindoxyl, MGM-15, MGM-16, and 7-hydroxymitragynine above a threshold into Schedule I, effective July 6, 2026. This impacts telehealth prescribing of kratom-derived substances.

Aforeworn detected this change in the Telehealth Cross-State Licensing space on July 6, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated High urgency. Telehealth platforms, virtual specialty clinics, behavioral-health providers, e-prescribers that prescribe or dispense kratom-derived substances. should confirm how it applies to their specific situation before acting. There is a time constraint attached: July 6, 2026. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Telehealth Cross-State Licensing continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.

What changed

DEA added mitragynine pseudoindoxyl, MGM-15, MGM-16, and 7-hydroxymitragynine above a specified threshold to Schedule I, making them illegal to prescribe or dispense without DEA registration.

Who it affects

Telehealth platforms, virtual specialty clinics, behavioral-health providers, e-prescribers that prescribe or dispense kratom-derived substances.

What you must do

Stop prescribing or dispensing these substances immediately upon effective date; review current patient prescriptions and transition to legal alternatives.

Deadline

July 6, 2026

Source: https://www.deadiversion.usdoj.gov/

Never miss a change like this again

Aforeworn watches Telehealth Cross-State Licensing around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.

Start your free trial

Related changes in Telehealth Cross-State Licensing